VEGFA and squamous cell carcinoma: This is in line with Baetke et al. who demonstrated a significant reduction in the amount of VEGFR2-targeted MB in heterotopic squamous cell carcinoma xenografts in mice undergoing anti-VEGF antibody therapy [24].